ArticleFrontiers in oncology2021
A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2025Pooled it
- Efficacy and safety of eltrombopag in the treatment of cancer therapy-induced thrombocytopenia: a large-scale, multicenter, retrospective study in China.Blood science (Baltimore, Md.) · 2026Article
- [Analysis of the efficacy and safety profile of the use of eltrombopag ethanolamine tablets in patients with cirrhotic thrombocytopenia].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Avatrombopag Reduces Platelet Transfusion Requirement in Thrombocytopenia Subsequent to Antineoplastic Therapies in Haematological Patients: The Experience of a Tertiary Centre.Journal of clinical medicine · 2026Article
- Efficacy of eltrombopag in combination with recombinant human thrombopoietin (rhTPO) for lymphoma patients with chemotherapy-induced thrombocytopenia.Frontiers in pharmacology · 2026Article
- Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.Research and practice in thrombosis and haemostasis · 2026Review
- Predicting the efficacy of recombinant human thrombopoietin in treating cancer therapy-related thrombocytopenia: based on stacking ensemble methods.Frontiers in oncology · 2026Article
- Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series.British journal of haematology · 2025Article
- Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management.Frontiers in immunology · 2025Review
- Recombinant human thrombopoietin therapy for primary immune thrombocytopenia in pregnancy: a retrospective comparative cohort study.BMC pregnancy and childbirth · 2023Article
- Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life.Cancers · 2023Review
- Effects of thrombopoietin pre-treatment on peri-liver transplantation thrombocytopenia in a mouse model of cirrhosis with hypersplenism.World journal of gastrointestinal surgery · 2023Article
- Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors.Research and practice in thrombosis and haemostasis · 2023Article
- Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia.Expert review of hematology · 2023Review
- The genomic landscape of sensitivity to arsenic trioxide uncovered by genome-wide CRISPR-Cas9 screening.Frontiers in oncology · 2023Article
- Combination regimen of granulocyte colony-stimulating factor and recombinant human thrombopoietin improves the curative effect on elderly patients with leukemia through inducing pyroptosis and ferroptosis of leukemia cells.Cancer gene therapy · 2022Article
- Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.Haematologica · 2022Article
- Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia following Autologous Stem Cell Transplant: Case Report and Review of the Literature.Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This real-world, observational study aimed to assess and compare the clinical efficacy and safety of eltrombopag with recombinant human thrombopoietin (rhTPO) in the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma. One hundred and fifty-three patients who experienced grade 3 or 4 thrombocytopenia after chemotherapy for lymphoma were enrolled, 51 of which were treated with eltrombopag, 50 with rhTPO, and 52 patients with no drug treatment were served as the control group. The lowest platelet level and mean platelet counts at Day 5, Day 7, and Day 10 were significantly higher in both the eltrombopag group (P=.041,.003,.000,.000) and rhTPO group (P=.005,.005,.000,.000) than the control, but there was no difference between treatment with eltrombopag and rhTPO. Similarly, days required for the recovery of platelet counts to ≥50×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.